Afya Reports Strong Q1 2026 Results with Focus on Shareholder Returns
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 49 minutes ago
0mins
Should l Buy AFYA?
Source: Newsfilter
- Revenue Growth: In Q1 2026, Afya's revenue increased by 8.2% year-over-year to R$1.0127 billion, with a 7.7% rise excluding acquisitions, indicating strong market demand and effective execution in the medical education sector.
- Adjusted EBITDA Performance: Adjusted EBITDA rose by 4.0% year-over-year to R$511.4 million, although the EBITDA margin decreased by 200 basis points to 50.5%, reflecting challenges in ongoing investments and cost management.
- Shareholder Return Strategy: The Board approved a cash dividend of R$307.4 million, representing 40% of 2025's net income, translating to R$3.446838 per share, underscoring the company's commitment to shareholder returns and robust financial health.
- User Growth and Ecosystem Expansion: Afya's ecosystem now boasts over 304,000 users, continuing to attract students and physicians, which strengthens its competitive edge in Brazil's medical education market while laying the groundwork for future B2B and B2P opportunities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AFYA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AFYA
Wall Street analysts forecast AFYA stock price to rise
5 Analyst Rating
1 Buy
4 Hold
0 Sell
Hold
Current: 14.220
Low
16.00
Averages
18.90
High
22.00
Current: 14.220
Low
16.00
Averages
18.90
High
22.00
About AFYA
Afya Ltd is a Brazil-based company engaged in the education sector. The Company is mainly focused on operating medical schools, offering health sciences courses, which comprise medicine, dentistry, nursing, radiology, psychology, pharmacy, physical education, physiotherapy, nutrition and biomedicine. In addition, the Firm provides degree programs and courses in other subjects and disciplines, including undergraduate and post graduate courses in business administration, accounting, law, civil engineering, industrial engineering and pedagogy. The Company's methodological approach combines integrated content, interactive learning, and an adaptive experience for learners. Through its educational content and technology-enabled activities, the Company focuses on personalized learning that mirrors one-on-one tutoring. The Company's undergraduate and graduate campuses are spread across Brazil, as well as its digital medical platform.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Afya Reports Strong Q1 2026 Results with Focus on Shareholder Returns
- Revenue Growth: In Q1 2026, Afya's revenue increased by 8.2% year-over-year to R$1.0127 billion, with a 7.7% rise excluding acquisitions, indicating strong market demand and effective execution in the medical education sector.
- Adjusted EBITDA Performance: Adjusted EBITDA rose by 4.0% year-over-year to R$511.4 million, although the EBITDA margin decreased by 200 basis points to 50.5%, reflecting challenges in ongoing investments and cost management.
- Shareholder Return Strategy: The Board approved a cash dividend of R$307.4 million, representing 40% of 2025's net income, translating to R$3.446838 per share, underscoring the company's commitment to shareholder returns and robust financial health.
- User Growth and Ecosystem Expansion: Afya's ecosystem now boasts over 304,000 users, continuing to attract students and physicians, which strengthens its competitive edge in Brazil's medical education market while laying the groundwork for future B2B and B2P opportunities.
See More
Afya Reaffirms AAA.br Credit Rating by Moody's
- Credit Rating Reaffirmed: Moody's has reaffirmed Afya's AAA.br credit rating and maintained a stable outlook, reflecting the company's leadership in Brazil's medical education sector and strong financial performance.
- Outstanding Financial Performance: The credit rating reflects Afya's revenue growth, above-industry-average margins, and exceptional cash generation capabilities, demonstrating robust financial management and liquidity.
- Clear Competitive Advantage: The company's strong competitive position in the medical education market and predictable financial policy, despite its appetite for M&As, maintain a solid credit profile, indicating the effectiveness of its business model.
- Long-Term Strategy Validation: Afya believes that this rating reaffirmation further validates its business model's sustainability, showcasing the company's consistency and financial discipline in achieving long-term strategic goals.
See More
Afya Ltd Reports Strong Growth in Earnings Call
- Significant Revenue Growth: Afya Ltd reported revenue of BRL 3.697 billion, marking a 12% year-over-year increase, indicating sustained demand and market leadership in medical education.
- Substantial EBITDA Increase: Adjusted EBITDA reached BRL 1.68 billion, growing over 50% year-over-year, with an EBITDA margin increase to 45.4%, showcasing the company's success in cost control and operational efficiency.
- Strong Cash Flow Performance: Cash flow from operating activities amounted to BRL 1.548 billion, a 6% increase from the previous year, providing a solid foundation for future investments and shareholder returns, reflecting the company's financial health.
- Commitment to Shareholder Returns: The company announced a cash dividend of BRL 307.4 million, equivalent to $0.45 per share, demonstrating a strong commitment to shareholder returns while also providing funding for future growth investments.
See More
Afyapress Releases Q4 2024 Financial Results
- Strong Financial Performance: Afyapress reported a Q4 Non-GAAP EPS of R$2.25 with revenue of R$912.99 million, reflecting a 7.5% year-over-year growth, indicating robust market growth potential.
- Adjusted EBITDA Growth: The adjusted EBITDA for Q4 increased by 6.1% to R$388.5 million, with an adjusted EBITDA margin of 42.6%, demonstrating effective management in cost control and profitability.
- Outstanding Cash Flow: The operating cash conversion ratio stood at 93.7%, with record free cash flow of R$1,056 million and a solid cash position of R$1,125.4 million, ensuring financial flexibility for future investments and operations.
- Positive 2026 Outlook: Building on a solid foundation from 2025 guidance achievements, Afyapress expects 2026 revenue to range between R$3,950 million and R$4,100 million, with adjusted EBITDA projected between R$1,700 million and R$1,800 million, reflecting confidence in future growth.
See More
Afya Reports Strong Earnings Beat, Positive Outlook Ahead
- Earnings Surprise: Afya reported earnings of $0.41 per share, exceeding the Zacks consensus estimate of $0.38, and up from $0.36 a year ago, indicating a solid improvement in profitability that is likely to boost investor confidence.
- Revenue Miss: Despite the earnings beat, Afya's quarterly revenue of $169.03 million fell short of the Zacks consensus estimate by 4.57%, highlighting challenges in revenue growth that could impact future market performance.
- Market Performance Analysis: Afya's shares have declined approximately 9.9% since the beginning of the year, compared to a 1% drop in the S&P 500, indicating relative weakness in the market, prompting investors to closely monitor future earnings expectations and industry trends.
- Outlook: The current consensus EPS estimate for Afya is $0.54 with projected revenues of $192.58 million, reflecting market confidence in the company's growth potential, and with a Zacks Rank of #2 (Buy), it suggests competitive strength and potential upside in the industry.
See More
Afya Reports Strong Financial Performance for 2025
- Significant Revenue Growth: In 2025, Afya's total revenue reached R$3,697.3 million, reflecting an 11.9% year-over-year increase, with revenue excluding acquisitions growing by 9.2%, indicating strong demand and market share expansion in Brazil's medical education sector.
- Adjusted EBITDA Performance: The adjusted EBITDA for 2025 was R$1,680.3 million, up 15.4% year-over-year, with an adjusted EBITDA margin increasing to 45.4%, demonstrating the company's ongoing improvements in cost control and operational efficiency.
- Substantial Net Income Increase: Afya reported a net income of R$768.4 million for 2025, an 18.4% increase, while adjusted net income grew by 9.9% to R$901.7 million, reflecting robust profitability and financial health.
- Cash Flow and Shareholder Returns: The company achieved a record free cash flow of R$1,056 million in 2025, and the board approved a cash dividend of R$307.4 million, showcasing strong capital allocation and shareholder return capabilities.
See More
Afya Reports Strong Q1 2026 Results with Focus on Shareholder Returns
- Revenue Growth: In Q1 2026, Afya's revenue increased by 8.2% year-over-year to R$1.0127 billion, with a 7.7% rise excluding acquisitions, indicating strong market demand and effective execution in the medical education sector.
- Adjusted EBITDA Performance: Adjusted EBITDA rose by 4.0% year-over-year to R$511.4 million, although the EBITDA margin decreased by 200 basis points to 50.5%, reflecting challenges in ongoing investments and cost management.
- Shareholder Return Strategy: The Board approved a cash dividend of R$307.4 million, representing 40% of 2025's net income, translating to R$3.446838 per share, underscoring the company's commitment to shareholder returns and robust financial health.
- User Growth and Ecosystem Expansion: Afya's ecosystem now boasts over 304,000 users, continuing to attract students and physicians, which strengthens its competitive edge in Brazil's medical education market while laying the groundwork for future B2B and B2P opportunities.
See More
Afya Reaffirms AAA.br Credit Rating by Moody's
- Credit Rating Reaffirmed: Moody's has reaffirmed Afya's AAA.br credit rating and maintained a stable outlook, reflecting the company's leadership in Brazil's medical education sector and strong financial performance.
- Outstanding Financial Performance: The credit rating reflects Afya's revenue growth, above-industry-average margins, and exceptional cash generation capabilities, demonstrating robust financial management and liquidity.
- Clear Competitive Advantage: The company's strong competitive position in the medical education market and predictable financial policy, despite its appetite for M&As, maintain a solid credit profile, indicating the effectiveness of its business model.
- Long-Term Strategy Validation: Afya believes that this rating reaffirmation further validates its business model's sustainability, showcasing the company's consistency and financial discipline in achieving long-term strategic goals.
See More
Afya Ltd Reports Strong Growth in Earnings Call
- Significant Revenue Growth: Afya Ltd reported revenue of BRL 3.697 billion, marking a 12% year-over-year increase, indicating sustained demand and market leadership in medical education.
- Substantial EBITDA Increase: Adjusted EBITDA reached BRL 1.68 billion, growing over 50% year-over-year, with an EBITDA margin increase to 45.4%, showcasing the company's success in cost control and operational efficiency.
- Strong Cash Flow Performance: Cash flow from operating activities amounted to BRL 1.548 billion, a 6% increase from the previous year, providing a solid foundation for future investments and shareholder returns, reflecting the company's financial health.
- Commitment to Shareholder Returns: The company announced a cash dividend of BRL 307.4 million, equivalent to $0.45 per share, demonstrating a strong commitment to shareholder returns while also providing funding for future growth investments.
See More
Afyapress Releases Q4 2024 Financial Results
- Strong Financial Performance: Afyapress reported a Q4 Non-GAAP EPS of R$2.25 with revenue of R$912.99 million, reflecting a 7.5% year-over-year growth, indicating robust market growth potential.
- Adjusted EBITDA Growth: The adjusted EBITDA for Q4 increased by 6.1% to R$388.5 million, with an adjusted EBITDA margin of 42.6%, demonstrating effective management in cost control and profitability.
- Outstanding Cash Flow: The operating cash conversion ratio stood at 93.7%, with record free cash flow of R$1,056 million and a solid cash position of R$1,125.4 million, ensuring financial flexibility for future investments and operations.
- Positive 2026 Outlook: Building on a solid foundation from 2025 guidance achievements, Afyapress expects 2026 revenue to range between R$3,950 million and R$4,100 million, with adjusted EBITDA projected between R$1,700 million and R$1,800 million, reflecting confidence in future growth.
See More
Afya Reports Strong Earnings Beat, Positive Outlook Ahead
- Earnings Surprise: Afya reported earnings of $0.41 per share, exceeding the Zacks consensus estimate of $0.38, and up from $0.36 a year ago, indicating a solid improvement in profitability that is likely to boost investor confidence.
- Revenue Miss: Despite the earnings beat, Afya's quarterly revenue of $169.03 million fell short of the Zacks consensus estimate by 4.57%, highlighting challenges in revenue growth that could impact future market performance.
- Market Performance Analysis: Afya's shares have declined approximately 9.9% since the beginning of the year, compared to a 1% drop in the S&P 500, indicating relative weakness in the market, prompting investors to closely monitor future earnings expectations and industry trends.
- Outlook: The current consensus EPS estimate for Afya is $0.54 with projected revenues of $192.58 million, reflecting market confidence in the company's growth potential, and with a Zacks Rank of #2 (Buy), it suggests competitive strength and potential upside in the industry.
See More
Afya Reports Strong Financial Performance for 2025
- Significant Revenue Growth: In 2025, Afya's total revenue reached R$3,697.3 million, reflecting an 11.9% year-over-year increase, with revenue excluding acquisitions growing by 9.2%, indicating strong demand and market share expansion in Brazil's medical education sector.
- Adjusted EBITDA Performance: The adjusted EBITDA for 2025 was R$1,680.3 million, up 15.4% year-over-year, with an adjusted EBITDA margin increasing to 45.4%, demonstrating the company's ongoing improvements in cost control and operational efficiency.
- Substantial Net Income Increase: Afya reported a net income of R$768.4 million for 2025, an 18.4% increase, while adjusted net income grew by 9.9% to R$901.7 million, reflecting robust profitability and financial health.
- Cash Flow and Shareholder Returns: The company achieved a record free cash flow of R$1,056 million in 2025, and the board approved a cash dividend of R$307.4 million, showcasing strong capital allocation and shareholder return capabilities.
See More
